2CUREX.ST
2cureX AB (publ) [2CUREX.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
2CUREX.ST Stock Summary
Top 10 Correlated Stocks
2CUREX.ST
In the News
2CUREX.ST Financial details
Company Rating
-
Market Cap
6.69M
Income
-29.95M
Revenue
167K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
22 Feb 2024
P/E
-0.97
Forward P/E
-
PEG
-1.08
P/S
134.32
P/B
1.88
P/C
-
P/FCF
-1.12
Quick Ratio
4.84
Current Ratio
5.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.7
EPS next Y
-
EPS next Q
-
EPS this Y
12.18%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
20.81%
Revenue last 5Y
-58.09%
Revenue Q/Q
-
EPS Q/Q
-51.72%
-
-
-
-
SMA20
69.44%
SMA50
45.24%
SMA100
27.08%
Inst Own
-
Inst Trans
-
ROA
-161%
ROE
-112%
ROC
-1.89%
Gross Margin
100%
Oper. Margin
-13441%
Profit Margin
-13865%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.286-7.66
52W High
-
52W Low
-
RSI
57.35
Rel Volume
0.32
Avg Volume
75.87K
Volume
24.6K
Perf Week
30.07%
Perf Month
98.34%
Perf Quarter
60.99%
Perf Half Y
47.13%
-
-
-
-
Beta
0.675
-
-
Volatility
0.06%, 0.23%
Prev Close
2.57%
Price
0.718
Change
10.8%
Company Profile
- Volume Average 75.87K
- Market Capitalization 6.69M
- Employee 14
- CEO Mr. Ole Thastrup VD
- Headquarters Copenhagen,DK
- IPO Date 2017-11-24
-
Website
https://www.2curex.com 
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
